While traditional treatments focus on glucose and lipid control, growing evidence suggests inflammation may continue Read More GLP-1 Adherence in the Real World: Why Patients Stop and How Clinicians Can Help Mar 17, 2026 Articles, Diabetes, GLP- 1 Agonist Therapy Center, GLP-1 Agonist Therapy Center, Type 2 Diabetes, Type 2 Diabetes 1,154 views Staying consistent with GLP-1 therapy remains one of the biggest challenges in diabetes management today
CJC-1295 (No DAC) / Ipamorelin / GHRP-2 Blend is a research peptide formulation combining three well-studied synthetic peptides commonly examined in growth hormone and endocrine signaling research: CJC-1295 without Drug Affinity Complex (No DAC), Ipamorelin, and Growth HormoneReleasing Peptide-2 (GHRP-2)
15 While the study showed a lower risk of sight-threatening retinopathy with SGLT2i, there was no increased risk with GLP-1 RAs compared with DPP-4i or sulfonylureas
Despite negotiated price reductions announced in November that the White House said would make the drugs available at a dramatically lower cost to taxpayers and enable Medicaid to cover them, states are going ahead with the cuts, which providers say may undermine patients health
